Royalty Pharma today released its financial results for the second quarter of 2024 and announced an increase in its full-year guidance for Portfolio Receipts. We achieved double-digit growth in Portfolio Receipts during the second quarter of 2024, surpassing our quarterly…
Bayer announced today that the FINEARTS-HF trial met its primary endpoint by achieving a statistically significant reduction in the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, including hospitalizations for HF or urgent HF visits.…
Amylyx Pharmaceuticals has received Orphan Drug Designation from the European Commission for AMX0035, its proprietary combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO) for treating Wolfram syndrome. This designation follows a positive opinion from the Committee for Orphan Medicinal Products…
Puma Biotechnology, a biopharmaceutical company, has released its financial results for the second quarter ending June 30, 2024. Comparisons are made between Q2 2024 and Q2 2023, unless specified otherwise. Product revenue, which comes entirely from sales of NERLYNX®, Puma’s…
Vertex Announces Q2 2024 Financial Results, Raises Full-Year Product Revenue Guidance Vertex today reported consolidated financial results for the second quarter ending June 30, 2024, and increased its full-year product revenue guidance to $10.65 to $10.85 billion. “Vertex achieved another…
Lilly announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg, or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.…
Biogen, Beckman Coulter, and Fujirebio have announced a collaboration to identify and develop blood-based biomarkers for tau pathology in Alzheimer’s disease (AD). The goal is to create new tests that measure tau burden in the brain, offering crucial insights into…
Vertex Announces FDA Acceptance of Suzetrigine NDA for Acute Pain Vertex Pharmaceuticals today revealed that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for suzetrigine, an investigational oral NaV1.8 pain signal inhibitor designed to…
Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along with its R&D, operational, and commercial sites, into Roche’s global…
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on updating the Wegovy® (semaglutide 2.4 mg) label. This update reflects data from the SELECT cardiovascular outcomes…
PROTEINA Co., Ltd., in partnership with Seoul National University (SNU) and Seoul National University Hospital (SNUH), has announced groundbreaking research published in Nature Biomedical Engineering. The study introduces a novel method for personalizing treatment for acute myeloid leukemia (AML) patients…
Verastem Oncology, a biopharmaceutical company focused on developing new cancer treatments, announced its intention to offer and sell shares of common stock and accompanying warrants to purchase common stock. The offering will also include pre-funded warrants, which can be purchased…